Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR
Osman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, David Pasquier, Felix Mottaghy, Ingo Einspieler, Nikolaos Kartalis, Irene Bargellini, Roberto Iezzi, Timm Denecke, Wolfgang Gerhard Kunz, Bernhard Gebauer, Henning Wege, Roberto Cannella, Daniela Elena Oprea-Lager
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHepatocellular Carcinoma Treatment and Prognosis · Cholangiocarcinoma and Gallbladder Cancer Studies · Cancer Mechanisms and Therapy
Correction to: European Radiology
10.1007/s00330-025-11699-7 published online 23 May 2025.
In the original article, affiliation of study group member Lorenza Rimassa’s affiliation was incorrectly given as IRCCS Humanitas Research Hospital, Roma, Italy. The correct affiliation is Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy.
Lorenza Rimassa is also affiliated with Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy, which was left out in the original article.
Furthermore, the following Conflict of interest statement was missing in the original article:
L.R. has received consulting fees from AbbVie, AstraZeneca, Basilea, Bayer, BMS, Elevar Therapeutics, Exelixis, Genenta, Hengrui, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; lecture fees from AstraZeneca, Bayer, BMS, Eisai, Guerbet, Incyte, Ipsen, Roche, Servier; travel expenses from AstraZeneca, Servier; and institutional research funding from AbbVie, AstraZeneca, BeiGene, Exelixis, Fibrogen, Incyte, Ipsen, Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, TransThera Sciences, Zymeworks.
The original article has been corrected.